Presentations & Webinars

SITC 2021: Actimab-A with Magrolimab CD47 Immunotherapy in AML

TCT 2021 Oral Presentation of SIERRA Results from 75% of Enrollment

Safety Results with Targeted Conditioning via Iomab-B

Register for CD33 Combination Trial KOL Call

Register for Iomab-ACT Update

Mid-Point Analysis of Pivotal Phase 3 SIERRA Trial Including Material Presented at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)

Dr. Sergio Giralt KOL Event – Interim Phase 3 SIERRA Results

Feasibility of Administering Iomab-B without Lead-Lined Rooms

Phase 3 SIERRA Dosimetry Data Supports Iomab-ACT Program ASH 2019

Actimab-A CLAG-M Combination Interim Results ASH 2019

• « Previous
• 1
• 2
• 3
• 4
• Next »